Advertisement
Organisation › Details
C4X Discovery (Group)
C4X Discovery aims to become the world’s most productive drug discovery and development Company by exploiting cutting-edge technologies to design and create best-in-class drug candidates. C4XD has a unique software platform for determining the 3D shape of drug molecules from experimental in vitro data that enables the rapid design and discovery of novel and potent drugs for diseases with high unmet medical need across broad therapeutic areas. The Company has a hybrid business model of wholly-owned programmes and partnerships with pharma, biotech and academics. The Company was founded in 2008 as a spin-out from the University of Manchester and has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically. *
Start | 2008-01-01 splitoff | |
Today | C4X Discovery Ltd. | |
Predecessor | University of Manchester (UoM) | |
Industry | drug discovery services | |
Industry 2 | NMR spectrometer | |
Person | Dix, Clive (C4X Discovery 2015– CEO before Convergence Pharma + PowderMed CEO + Co-founder) | |
Region | Manchester, Greater Manchester | |
Country | United Kingdom (GB) | |
Street | Portland Street Manchester One | |
City | M1 3LD Manchester | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: | ||
Record changed: 2023-07-10 |
Advertisement
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top